{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:40:21Z","timestamp":1792896021841,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41588-026-02580-4","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T09:04:00Z","timestamp":1777280640000},"page":"1100-1111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study"],"prefix":"10.1038","volume":"58","author":[{"given":"Luana","family":"Calabr\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca P.","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Covre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6752","authenticated-orcid":false,"given":"Teresa M. R.","family":"Noviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Lofiego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9158-3533","authenticated-orcid":false,"given":"Rossella","family":"Tufano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Grisolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2396-3101","authenticated-orcid":false,"given":"Antonio","family":"De Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5965-0361","authenticated-orcid":false,"given":"Vincenzo","family":"Lagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sgambelluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Sabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gibilisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9399-4511","authenticated-orcid":false,"given":"Francesco","family":"Marzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-377X","authenticated-orcid":false,"given":"Vincenzo","family":"D\u2019Alonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Coral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Cerbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9862-7340","authenticated-orcid":false,"given":"Sara","family":"Delfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Mortarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Anichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4702-6617","authenticated-orcid":false,"given":"Michele","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2580_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","volume":"6","author":"L Calabr\u00f2","year":"2018","unstructured":"Calabr\u00f2, L. et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir. Med. 6, 451\u2013460 (2018).","journal-title":"Lancet Respir. Med."},{"key":"2580_CR2","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","volume":"9","author":"L Calabr\u00f2","year":"2021","unstructured":"Calabr\u00f2, L. et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir. Med. 9, 969\u2013976 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2580_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst, M. J. et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir. Med. 7, 260\u2013270 (2019).","journal-title":"Lancet Respir. Med."},{"key":"2580_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel, A. et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 20, 239\u2013253 (2019).","journal-title":"Lancet Oncol."},{"key":"2580_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375\u2013386 (2021).","journal-title":"Lancet"},{"key":"2580_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.lungcan.2014.08.017","volume":"86","author":"AS Mansfield","year":"2014","unstructured":"Mansfield, A. S., Symanowski, J. T. & Peikert, T. Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. Lung Cancer 86, 133\u2013136 (2014).","journal-title":"Lung Cancer"},{"key":"2580_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters, S. et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann. Oncol. 33, 488\u2013499 (2022).","journal-title":"Ann. Oncol."},{"key":"2580_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61691-4","volume":"16","author":"DA Fennell","year":"2025","unstructured":"Fennell, D. A. et al. Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial. Nat. Commun. 16, 6688 (2025).","journal-title":"Nat. Commun."},{"key":"2580_CR9","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.3390\/ijms23105786","volume":"23","author":"L Mannarino","year":"2022","unstructured":"Mannarino, L. et al. Epithelioid pleural mesothelioma is characterized by tertiary lymphoid structures in long survivors: results from the MATCH study. Int. J. Mol. Sci. 23, 5786 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2580_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum, Y. et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat. Commun. 10, 1333 (2019).","journal-title":"Nat. Commun."},{"key":"2580_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"2580_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49842-5","volume":"15","author":"M Zhang","year":"2024","unstructured":"Zhang, M. et al. A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma. Nat. Commun. 15, 7187 (2024).","journal-title":"Nat. Commun."},{"key":"2580_CR13","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","volume":"14","author":"B Giotti","year":"2024","unstructured":"Giotti, B. et al. Single-cell view of tumor microenvironment gradients in pleural mesothelioma. Cancer Discov. 14, 2262\u20132278 (2024).","journal-title":"Cancer Discov."},{"key":"2580_CR14","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-14-2914","volume":"21","author":"M Maio","year":"2015","unstructured":"Maio, M. et al. Molecular pathways: at the crossroads of cancer epigenetics and immunotherapy. Clin. Cancer Res. 21, 4040\u20134047 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2580_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.03.036","volume":"169","author":"KB Chiappinelli","year":"2017","unstructured":"Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 169, 361 (2017).","journal-title":"Cell"},{"key":"2580_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng, D. et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249\u2013253 (2015).","journal-title":"Nature"},{"key":"2580_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung, H. et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat. Commun. 10, 4278 (2019).","journal-title":"Nat. Commun."},{"key":"2580_CR18","doi-asserted-by":"publisher","first-page":"e002226","DOI":"10.1136\/jitc-2020-002226","volume":"9","author":"K Filipski","year":"2021","unstructured":"Filipski, K. et al. DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma. J. Immunother. Cancer 9, e002226 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2580_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00907-4","volume":"12","author":"JY Kim","year":"2020","unstructured":"Kim, J. Y., Choi, J. K. & Jung, H. Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer. Clin. Epigenetics 12, 119 (2020).","journal-title":"Clin. Epigenetics"},{"key":"2580_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03474-9","volume":"44","author":"A Anichini","year":"2025","unstructured":"Anichini, A. et al. Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanoma. J. Exp. Clin. Cancer Res. 44, 212 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2580_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03310-0","volume":"44","author":"MF Lofiego","year":"2025","unstructured":"Lofiego, M. F. et al. DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy. J. Exp. Clin. Cancer Res. 44, 58 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2580_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04012-4","volume":"74","author":"H Zhang","year":"2025","unstructured":"Zhang, H., Yu, L., Guo, Y., Ming, J. & Guo, Z. DNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma. Cancer Immunol. Immunother. 74, 158 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"2580_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40994-4","volume":"14","author":"TMR Noviello","year":"2023","unstructured":"Noviello, T. M. R. et al. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. Nat. Commun. 14, 5914 (2023).","journal-title":"Nat. Commun."},{"key":"2580_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1158\/1078-0432.CCR-22-2566","volume":"29","author":"H-S Lee","year":"2023","unstructured":"Lee, H.-S. et al. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin. Cancer Res. 29, 548\u2013559 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2580_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","volume":"3","author":"L Calabr\u00f2","year":"2015","unstructured":"Calabr\u00f2, L. et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir. Med. 3, 301\u2013309 (2015).","journal-title":"Lancet Respir. Med."},{"key":"2580_CR26","doi-asserted-by":"publisher","first-page":"e000617","DOI":"10.1136\/jitc-2020-000617","volume":"8","author":"J Roelands","year":"2020","unstructured":"Roelands, J. et al. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. J. Immunother. Cancer 8, e000617 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2580_CR27","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"2580_CR28","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545\u20131549 (2018).","journal-title":"Nat. Med."},{"key":"2580_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04705-3","volume":"22","author":"M Mason","year":"2024","unstructured":"Mason, M. et al. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer. J. Transl. Med. 22, 190 (2024).","journal-title":"J. Transl. Med."},{"key":"2580_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541 (2022).","journal-title":"Immunity"},{"key":"2580_CR31","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41416-020-01145-4","volume":"124","author":"T Turan","year":"2021","unstructured":"Turan, T. et al. A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. Br. J. Cancer 124, 760\u2013769 (2021).","journal-title":"Br. J. Cancer"},{"key":"2580_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","volume":"55","author":"L Mangiante","year":"2023","unstructured":"Mangiante, L. et al. Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Nat. Genet. 55, 607\u2013618 (2023).","journal-title":"Nat. Genet."},{"key":"2580_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.abd1329","volume":"372","author":"KE Yost","year":"2021","unstructured":"Yost, K. E., Chang, H. Y. & Satpathy, A. T. Recruiting T cells in cancer immunotherapy. Science 372, 130\u2013131 (2021).","journal-title":"Science"},{"key":"2580_CR34","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"2580_CR35","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548\u20131565 (2018).","journal-title":"Cancer Discov."},{"key":"2580_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0857-2","volume":"17","author":"C-H Yeh","year":"2018","unstructured":"Yeh, C.-H., Bellon, M. & Nicot, C. FBXW7: a critical tumor suppressor of human cancers. Mol. Cancer 17, 115 (2018).","journal-title":"Mol. Cancer"},{"key":"2580_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ccell.2014.09.013","volume":"26","author":"RJ Davis","year":"2014","unstructured":"Davis, R. J., Welcker, M. & Clurman, B. E. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell 26, 455\u2013464 (2014).","journal-title":"Cancer Cell"},{"key":"2580_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: gGenome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"2580_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"key":"2580_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han, G. et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat. Commun. 12, 5606 (2021).","journal-title":"Nat. Commun."},{"key":"2580_CR41","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1158\/1078-0432.CCR-19-3573","volume":"26","author":"C Pirker","year":"2020","unstructured":"Pirker, C. et al. Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup. Clin. Cancer Res. 26, 3819\u20133830 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2580_CR42","doi-asserted-by":"publisher","first-page":"7351","DOI":"10.1158\/1078-0432.CCR-19-1335","volume":"25","author":"AM Di Giacomo","year":"2019","unstructured":"Di Giacomo, A. M. et al. Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial. Clin. Cancer Res. 25, 7351\u20137362 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2580_CR43","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1073\/pnas.1703577114","volume":"114","author":"X Hao","year":"2017","unstructured":"Hao, X. et al. DNA methylation markers for diagnosis and prognosis of common cancers. Proc. Natl Acad. Sci. USA 114, 7414\u20137419 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2580_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25661-w","volume":"12","author":"RN Batra","year":"2021","unstructured":"Batra, R. N. et al. DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. Nat. Commun. 12, 5406 (2021).","journal-title":"Nat. Commun."},{"key":"2580_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01226-y","volume":"14","author":"C Kuang","year":"2022","unstructured":"Kuang, C. et al. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. Clin. Epigenetics 14, 3 (2022).","journal-title":"Clin. Epigenetics"},{"key":"2580_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021800","volume":"6","author":"F Supek","year":"2011","unstructured":"Supek, F., Bo\u0161njak, M., \u0160kunca, N. & \u0160muc, T. REVIGO summarizes and visualizes long lists of Gene Ontology terms. PLoS ONE 6, e21800 (2011).","journal-title":"PLoS ONE"},{"key":"2580_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"2580_CR48","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/s41587-024-02382-1","volume":"43","author":"S Behera","year":"2025","unstructured":"Behera, S. et al. Comprehensive genome analysis and variant detection at scale using DRAGEN. Nat. Biotechnol. 43, 1177\u20131191 (2025).","journal-title":"Nat. Biotechnol."},{"key":"2580_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80\u201392 (2012).","journal-title":"Fly (Austin)"},{"key":"2580_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"2580_CR51","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248\u2013249 (2010).","journal-title":"Nat. Methods"},{"key":"2580_CR52","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1101\/gr.176601","volume":"11","author":"CN Pauline","year":"2001","unstructured":"Pauline, C. N. & Henikoff, S. Predicting deleterious amino acid substitutions. Genome Res. 11, 863\u2013874 (2001).","journal-title":"Genome Res."},{"key":"2580_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046688","volume":"7","author":"Y Choi","year":"2012","unstructured":"Choi, Y., Sims, G. E., Murphy, S., Miller, J. R. & Chan, A. P. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE 7, e46688 (2012).","journal-title":"PLoS ONE"},{"key":"2580_CR54","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","volume":"8","author":"J Hundal","year":"2020","unstructured":"Hundal, J. et al. pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol. Res. 8, 409\u2013420 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"2580_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-019-0369-7","volume":"2","author":"J Zhang","year":"2019","unstructured":"Zhang, J. et al. The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival. Commun. Biol. 2, 135 (2019).","journal-title":"Commun. Biol."},{"key":"2580_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"2580_CR57","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"2580_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-480","volume":"12","author":"D Risso","year":"2011","unstructured":"Risso, D., Schwartz, K., Sherlock, G. & Dudoit, S. GC-content normalization for RNA-seq data. BMC Bioinformatics 12, 480 (2011).","journal-title":"BMC Bioinformatics"},{"key":"2580_CR59","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2580_CR60","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"2580_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1664-9","volume":"20","author":"F M\u00fcller","year":"2019","unstructured":"M\u00fcller, F. et al. RnBeads 2.0: comprehensive analysis of DNA methylation data. Genome Biol. 20, 55 (2019).","journal-title":"Genome Biol."},{"key":"2580_CR62","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572\u20131573 (2010).","journal-title":"Bioinformatics"},{"key":"2580_CR63","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature25171","volume":"553","author":"V Frattini","year":"2018","unstructured":"Frattini, V. et al. A metabolic function of FGFR3\u2013TACC3 gene fusions in cancer. Nature 553, 222\u2013227 (2018).","journal-title":"Nature"},{"key":"2580_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-0721-z","volume":"12","author":"J Fu","year":"2020","unstructured":"Fu, J. et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 12, 21 (2020).","journal-title":"Genome Med."},{"key":"2580_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1113-y","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Erratum to: estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 249 (2016).","journal-title":"Genome Biol."},{"key":"2580_CR66","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1093\/nar\/gkad841","volume":"51","author":"S M\u00fcller-Dott","year":"2023","unstructured":"M\u00fcller-Dott, S. et al. Expanding the coverage of regulons from high-confidence prior knowledge for accurate estimation of transcription factor activities. Nucleic Acids Res. 51, 10934\u201310949 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2580_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky015","volume":"46","author":"R Mall","year":"2018","unstructured":"Mall, R. et al. RGBM: regularized gradient boosting machines for identification of the transcriptional regulators of discrete glioma subtypes. Nucleic Acids Res. 46, e39 (2018).","journal-title":"Nucleic Acids Res."},{"key":"2580_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83858-x","volume":"11","author":"ER Parra","year":"2021","unstructured":"Parra, E. R. et al. Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Sci. Rep. 11, 4530 (2021).","journal-title":"Sci. Rep."},{"key":"2580_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"2580_CR70","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1038\/s41596-019-0202-2","volume":"14","author":"SY Shen","year":"2019","unstructured":"Shen, S. Y., Burgener, J. M., Bratman, S. V. & De Carvalho, D. D. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. Nat. Protoc. 14, 2749\u20132780 (2019).","journal-title":"Nat. Protoc."},{"key":"2580_CR71","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"2580_CR72","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"2580_CR73","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/bioinformatics\/btt650","volume":"30","author":"M Lienhard","year":"2014","unstructured":"Lienhard, M., Grimm, C., Morkel, M., Herwig, R. & Chavez, L. MEDIPS: genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments. Bioinformatics 30, 284\u2013286 (2014).","journal-title":"Bioinformatics"},{"key":"2580_CR74","doi-asserted-by":"publisher","unstructured":"Calabr\u00f2, L. et al. Tumor methylation subtypes predict the clinical outcome to immunotherapy in pleural mesothelioma patients: the NIBIT-EPI-MESO study (version 1) [data set]. Zenodo https:\/\/doi.org\/10.5281\/zenodo.16601674 (2025).","DOI":"10.5281\/zenodo.16601674"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02580-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02580-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02580-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:02:29Z","timestamp":1778778149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02580-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2580"],"URL":"https:\/\/doi.org\/10.1038\/s41588-026-02580-4","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L. Calabr\u00f2 has received compensation for educational activities from Bristol Myers Squibb, AstraZeneca, Regeneron, Merck Sharp & Dohme, Roche and Viatris. A.C. and S.C. own shares in Epigen Therapeutics. L. Cerbone reports support for attending meetings or travel from Pierre Fabre. F.G. reports consulting fees and support for attending meetings or travel from Merck Sharp & Dohme, Novocure, Bristol Myers Squibb, Boehringer Ingelheim, PharmaMar, Novartis and Pierre Fabre; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Novocure; and participation on a data safety monitoring board or advisory board for Merck Sharp & Dohme, Novocure, Bristol Myers Squibb, PharmaMar, Novartis and Pierre Fabre. A.M.D.G. has served as consultant and\/or advisor to Incyte, Pierre Fabre, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme and Sanofi, and has received compensation for educational activities from Bristol Myers Squibb, Merck Sharp & Dohme, Pierre Fabre and Sanofi. M. Milione has served as consultant and\/or advisor to Novartis, Ipsen, Roche, Sakura Finetek, Leica, Diapath, Bioptica and Merck Sharp & Dohme, and has received financial support for clinical trials from Ignyta, Roche, ADOPT BBMRI-ERIC, TRANSCAN2 and Fondazione IRCCS Istituto Nazionale Tumori Milano. M. Ceccarelli received funding from Moderna Therapeutics and is the founder and shareholder of Immunomica. M. Maio has served as consultant and\/or advisor to Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, GlaxoSmithKline, Sciclone, Sanofi, Alfasigma and Merck Serono, and shareholder in Epigen Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}